Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.

NCT04826159 is registered in ClinicalTrials.gov with Imbria Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04826159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04826159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.
Lead sponsor
Imbria Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 21, 2021
Completion date
August 6, 2024
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic cardiomyopathies, hfpef - heart failure with preserved ejection fraction, type 2 diabetes